Earnings summaries and quarterly performance for GMRE.
Executive leadership at GMRE.
Board of directors at GMRE.
Research analysts who have asked questions during GMRE earnings calls.
AW
Austin Wurschmidt
KeyBanc Capital Markets Inc.
6 questions for GMRE
Also covers: AHR, AIV, AMH +20 more
Gaurav Mehta
Alliance Global Partners
6 questions for GMRE
Also covers: ALEX, BRSP, CCIF +15 more
Juan Sanabria
BMO Capital Markets
5 questions for GMRE
Also covers: AHR, AMH, BRX +22 more
WG
Wesley Golladay
Robert W. Baird & Co.
3 questions for GMRE
Also covers: ADC, AHR, ARE +25 more
John Massocca
B. Riley Financial
2 questions for GMRE
Also covers: BEEP, CMCT, CTO +13 more
Robert Stevenson
Janney Montgomery Scott LLC
2 questions for GMRE
Also covers: ADC, AHH, AIV +17 more
WG
Wes Golladay
Baird
2 questions for GMRE
Also covers: AHR, CTRE, DOC +7 more
Alec Feygin
Robert W. Baird & Co. Incorporated
1 question for GMRE
Also covers: CTRE, FCPT, KIM +6 more
BM
Bryan Maher
B. Riley Securities
1 question for GMRE
Also covers: BEEP, DHC, GNL +8 more
Robin Haneland
BMO Capital Markets
1 question for GMRE
Also covers: NHI, NSA
Recent press releases and 8-K filings for GMRE.
Chiron Real Estate Reports Q4 2025 Results, Announces Strategic Shift to Seniors Housing, and Provides 2026 Guidance
GMRE
Earnings
Guidance Update
New Projects/Investments
- Chiron Real Estate (GMRE) reported Q4 2025 Core FFO of $1.16 per share and unit and a 5.4% year-over-year increase in same-store cash NOI, with net debt to adjusted EBITDAre at 6.2 times.
- The company issued initial 2026 Core FFO guidance of $4.30-$4.45 per share and unit and will transition to a monthly dividend at an annual rate of $3 per share.
- GMRE is strategically expanding its investment focus to include active adult and seniors housing, specifically targeting premium, newly built independent, assisted living, and memory care properties due to their superior growth prospects.
- To support this strategy, the company has identified approximately $250 million in prospective dispositions, including IRF assets and the Beaumont Surgical Hospital, and has already sold a medical office for $10 million.
- An initial new investment includes a 49% interest in an active adult development in Minneapolis, expected to be delivered in 2027 with a stabilized double-digit unlevered IRR.
2 days ago
Chiron (formerly GMRE) Reports Q4 2025 Results and Provides 2026 Guidance
GMRE
Earnings
Guidance Update
Debt Issuance
- The company, now operating under the new identity Chiron, reported a $1.5 billion real estate portfolio that is 96% leased and achieved +5.4% Same Store NOI Growth for the fourth quarter of 2025.
- Chiron undertook significant balance sheet fortification in Q4 2025, including a credit facility recast, a $50 million preferred equity issuance at an 8.0% yield, and $6 million in share repurchases at a weighted average price of $34.16 per share. These actions contributed to an improved debt term remaining of 4.1 years and a Net Debt / Adj. EBITDAre of 6.2x as of December 31, 2025.
- For 2026, the company projects Core FFO per diluted share guidance of $4.30 - $4.45, a decrease from $4.53 in 2025, primarily due to the financial impact of balance sheet fortification.
- Recent strategic investment activities include a $7 million equity investment in an Active Adult Minneapolis Development Joint Venture in January 2026 and the sale of Marina Towers for $10 million in December 2025.
2 days ago
Chiron Real Estate Reports Q4 2025 Results, Announces Strategic Shift to Seniors Housing and 2026 Guidance
GMRE
Earnings
Guidance Update
New Projects/Investments
- Chiron Real Estate reported Q4 2025 Nareit defined FFO of $0.97 per share and Core FFO of $1.16 per share, with same-store cash NOI increasing 5.4% year-over-year and 2.9% sequentially.
- The company announced a strategic expansion into active adult and seniors housing, aiming to build a differentiated portfolio of premium, newly built assets, funded through capital recycling.
- Chiron provided initial 2026 Core FFO guidance in the range of $4.30 to $4.45 per share and will transition to a monthly dividend at the current annual rate of $3 per share.
- The balance sheet has been fortified, with no debt maturing before 2028, and the company plans approximately $250 million in prospective dispositions to fund new investments.
2 days ago
Chiron Real Estate Reports Q4 2025 Results, Issues 2026 Guidance, and Announces Strategic Shift to Seniors Housing
GMRE
Earnings
Guidance Update
New Projects/Investments
- Chiron Real Estate reported Q4 2025 NAREIT defined FFO per share and unit of $0.97 and Core FFO per share and unit of $1.16, with same-store cash NOI increasing 5.4% on a year-over-year basis.
- The company issued initial 2026 Core FFO guidance of $4.30-$4.45 per share and unit, which includes $0.36 in anticipated headwinds from balance sheet fortification efforts.
- Chiron announced a transition to a monthly dividend, maintaining the annual rate at $3 per share.
- The company is strategically expanding its investment focus into active adult and seniors housing, emphasizing premium, newly built assets, and plans to fund these new investments through capital recycling, having identified approximately $250 million in prospective dispositions.
- The balance sheet was strengthened, with net debt to adjusted EBITDAre at 6.2 times for Q4 2025, representing a 0.7 times reduction from the prior period, and the company has no debt maturing before 2028.
2 days ago
Chiron Real Estate Inc. Announces Q4 and Full Year 2025 Financial Results, Corporate Rebrand, and 2026 Guidance
GMRE
Earnings
Guidance Update
Dividends
- Chiron Real Estate Inc. (formerly Global Medical REIT Inc.) reported a net loss of $7.4 million, or $0.55 per diluted share, and Core FFO of $1.16 per share for the fourth quarter of 2025. The company also achieved 5.4% year-over-year Same-Property Cash NOI growth.
- The company completed a corporate rebrand from Global Medical REIT Inc. to Chiron Real Estate Inc., effective February 23, 2026, with its NYSE ticker changing from GMRE to XRN.
- Chiron provided 2026 Core FFO guidance of $4.30 to $4.45 per diluted share and announced a transition to monthly common dividends starting April 2026, maintaining an annualized dividend rate of $3.00 per share.
- During Q4 2025, the company repurchased 175,634 common shares for $6.0 million and completed a public offering of Series B Preferred Stock for gross proceeds of $51.3 million.
3 days ago
Global Medical REIT Inc. Announces Issuance of 8.00% Series B Cumulative Redeemable Preferred Stock
GMRE
Dividends
Convertible Preferred Issuance
- Global Medical REIT Inc. (GMRE) announced the issuance and sale of 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock at a public offering price of $25.00 per share, totaling $50,000,000.
- The Series B Preferred Stock will pay cumulative cash dividends at an annual rate of 8.00% (equivalent to $2.00 per annum per share), accruing from November 20, 2025.
- Dividends will be paid quarterly in arrears on January 31, April 30, July 31, and October 31 of each year, commencing January 31, 2026.
- The stock is perpetual but redeemable by GMRE on or after November 20, 2030, at $25.00 per share plus accrued and unpaid dividends, and includes a conversion right for holders upon a change of control.
- GMRE intends to file an application to list the Series B Preferred Stock on the NYSE under the symbol "GMRE-PrB".
Nov 18, 2025, 9:15 PM
Global Medical REIT Inc. Reports Q3 2025 Results
GMRE
Earnings
Debt Issuance
- Global Medical REIT Inc. reported a net loss attributable to common stockholders of approximately $6.0 million, or $0.45 per diluted share, for the third quarter ended September 30, 2025.
- For the third quarter of 2025, the company achieved 2.7% year-over-year same-store cash net operating income growth.
- As of September 30, 2025, the company's portfolio was 95.2% occupied, comprising approximately 5.2 million leasable square feet with an annualized base rent of approximately $118.4 million.
- The Net Debt / Annualized Adjusted EBITDA_re_ ratio for the quarter ended September 30, 2025, was 6.9x.
Nov 13, 2025, 1:45 PM
GLOBAL MEDICAL REIT Reports Q3 2025 Results
GMRE
Earnings
Share Buyback
Debt Issuance
- GLOBAL MEDICAL REIT reported a net loss attributable to common stockholders of $6.0 million, or $0.45 per diluted share, for Q3 2025, primarily due to a $6.3 million impairment charge related to a facility in Aurora, IL.
- Funds from operations (FFO) increased to $14.5 million, or $1.00 per share and unit, and Adjusted funds from operations (AFFO) increased to $16.2 million, or $1.12 per share and unit, both representing a 4% year-over-year increase on a per share and unit basis.
- As of September 30, 2025, the company maintained a portfolio leased occupancy of 95.2% and achieved Same-Store Cash Net Operating Income (NOI) growth of 2.7% on a year-over-year basis.
- In September 2025, GLOBAL MEDICAL REIT completed a one-for-five reverse stock split, and in August 2025, established a $50 million common stock repurchase program, though no shares had been repurchased as of November 3, 2025.
- Consolidated debt outstanding was $713 million as of September 30, 2025, with a leverage ratio of 47.3% and Net Debt / Annualized Adjusted EBITDAre of 6.9x. The credit facility was amended in October 2025 to extend maturities.
Nov 5, 2025, 2:00 PM
GMRE Reports Q3 2025 Financial Results and Strategic Updates
GMRE
Earnings
Debt Issuance
Share Buyback
- Global Medical REIT (GMRE) reported Q3 2025 Funds From Operations (FFO) of $1.00 per share and Adjusted Funds From Operations (AFFO) of $1.12 per share, with both metrics growing 4% on a per-share basis relative to the prior year.
- The company's portfolio achieved 2.7% same-store Net Operating Income (NOI) growth and was 95.2% leased with a 5.3-year weighted average lease term (WALT) as of quarter-end, with expectations for occupancy to trend towards 96% by year-end.
- GMRE proactively managed its balance sheet by extending its revolver to 2029 and its $350 million term loan A into three tranches maturing between October 2029 and April 2031, while also removing a 10 basis point SOFR credit spread from its credit facility borrowings.
- The company is evaluating a $500 million acquisition pipeline with 7.5%-8% first-year cash returns and plans to fund transactions through asset recycling, with a near-term disposition pipeline of $50-$100 million, and is also considering share buybacks and preferred stock as capital options.
Nov 5, 2025, 2:00 PM
Global Medical REIT Announces Third Quarter 2025 Financial Results
GMRE
Earnings
Share Buyback
Debt Issuance
- Global Medical REIT Inc. reported a net loss attributable to common stockholders of $6.0 million, or $0.45 per diluted share, for the third quarter of 2025, primarily due to a $6.3 million impairment charge. Despite this, Funds From Operations (FFO) increased 4% year-over-year to $1.00 per share and unit, and Adjusted Funds From Operations (AFFO) increased 4% year-over-year to $1.12 per share and unit.
- Rental revenue grew 8.4% year-over-year to $37.0 million for Q3 2025, with Same-Store Cash Net Operating Income (NOI) growth of 2.7%. Portfolio leased occupancy stood at 95.2% as of September 30, 2025.
- The company completed a one-for-five reverse stock split in September 2025 and established a $50 million common stock repurchase program in August 2025. Additionally, in October 2025, the credit facility was amended to extend maturities, increasing the weighted average maturity from 1.3 years to 4.4 years.
Nov 4, 2025, 10:04 PM
Quarterly earnings call transcripts for GMRE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more